Abstract:Background: Hepatic inflammatory and fibrotic lesions promote the development of cirrhosir and hepatocellular carcinoma in patients with chronic Hepatitis 8 (CHB). Farly recognition of hepatic histopathological changes and timely initiation of antivical therapy can delay or even reverse disease progression. Objectives: This study aimed to analyze non invasive diagnostic indicators associated inch different inflammation grades, fibrosis stages, and Hepatios degrees in CHB patients, and their outcomes after antiviral therapy Methods: A total of si CHB patients treated at the Third People's Hospital of Shenzhen from January December 2019 were selected for inflammation grading (G) and fibrous staging (5) based on liver puncture examination results. The patients were further dirnded into mild, moderate, and severe chronic Hepatitis groups. Correlation analysis was conducted via Spearman. The diagnostic performance of the relevant indexes for inflammation grading, bibrosi staging, and Hepatios degree grading was evaluated using receiver operator characteristics (ROC) The performance of different ROC curves was further compared using the DeLong rest. The effects of of antiviral drugs on patients with different liver hutopathological degrees were comparatively analyzed after 24, 48, 72, and 95 weeks. Results: Data analysis at baseline showed that 86.81% (79 of 91) of all patients were male. Additionally, about 61.54% (16 of 26), 30.77% (8 of 26), 85.19% (23 of 27), and 62.96% (17 of 27) of patients with normal ALT had G >= 2, G >= 3, S >= 2, and S >= 3, respectively inflammation grade, fibrosis stage, and Hepatitis degree were positively correlated with portal vein internal diameter, spleen thickness. LN, GPR, FIB-4, and 5 index, and negatively correlated with PLT (P<0.05). The area under the curve (AUC) of the ROC assessed multifactorial combinations PSUPTL, PSWPAHPCL, and PSWPHCL for predicting the risk of developing G3 inflammation, 5:3 fibrosis, and moderate to severe Hepatitis in patients with CHB were 0.806, 0.843, and 0.778, respectively. The diagnostic accuracies were higher than some of these factors applied indindually and some commonly used serological markers. HBV DNA levels were significantly lower in different Hepatitis groups after 24 werks of antiviral therapy than before treatment (P<0.05). Furthermore, the ALT normalization rate and HBV DNA clearance rate were slightly higher in the moderate and severe groups than in the mild group alter 48 werks of treatment (P>0.05). The serum liepatitis B envelope antigen (HBeAg) level was nguficantly lower in the severe group than in the mild group after 72 weeks of antiviral therapy (H7.043, P=0.030). Although only the HBeAg serologic conversion rate was significantly different at 96 weeks among the three groups (chi(2) = 12389,P=0.002), (BeAg negative and the serologic conversion rates higher in the severe group at each time point than in the mild and moderate groups Conclusions: Multiple non invasive indicators are strongly associated with different degrees of liver histopathology in patients with chronic HBV infection. Therefore, PSBPTL, PSWPAHPCI, and PSWPHCL can be used to predict the risk of developing Gas inflammation, 53 fibrosis, and moderate to severe Hepatitis in these pacients, respectively. Moreover, short term anuviral therapy has a more pronounced effect on patients with severe Hepatitis by improving hepatic inflammation and inhibiting viral replication.

[A Prospective Study of Histological Changes after AraAMP Treatment in Patients with Chronic Hepatitis B Infection].

[Effects of Autologous Peripheral Stem Cell Transplantation on Acoustic Radiation Force Impulse in Patients with HBV-related Decompensated Cirrhosis].

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

[Highly Active Antiretroviral Therapy on Liver Function in HIV-positive Children with HBV/HCV Co-Infection].

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

Clinical Trail of Decoction of Tonifying Qi Activating Blood and Detoxifcation in the Treatment of Chronic Hepatitis B Patients with Alanine Aminotransferase Less than Two-time upper Limits of Normal Level

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Responding to Peg-IFN Treatment

Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study.

Hepatic histological changes after 48 weeks adefovir dipivoxil treatment in patients with HBeAg- positive chronic hepatitis B

Liver Fibrosis and Hepatic Stellate Cells Improvement of Chronic Hepatitis C Patients by Interferon-Beta-1a with or Without Sustained Viral Response.

Predictors of Inflammatory Activity in Treatment-Naive Hepatitis B E-Antigen-negative Patients with Chronic Hepatitis B Infection

Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels.

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

Non-ALT Biomarkers for Markedly Abnormal Liver Histology among Chinese Persistently Normal Alanine Aminotransferase-Chronic Hepatitis B Patients.

Non-invasive Diagnostic Indicators and Antiviral Treatment Efficacy in CHB Patients with Different Liver Histopathological Degrees

Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.

[Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients].

Histological Responses of Peginterferon Alpha Add-on Therapy in Patients with Chronic Hepatitis B with Advanced Liver Fibrosis after Long-Term Nucleos(t)ide Analog Treatment

Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trial

Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B

Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy